Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Proteolysis-targeting chimera (PROTAC) targeting bruton tyrosine kinase (BTK) degradation for cancer therapy in mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXianhuo WangHZHuilai Zhang

Discussion

Loading...

Member takes

Overview

Functional analysis reveals that PROTAC effectively overcomes acquired resistance in mantle cell lymphoma, suggesting potential for improved therapy.

Key Points

  • Acquired resistance in mantle cell lymphoma challenges treatment options, making effective therapies essential.
  • Functional assays indicated that C23 PROTAC significantly degraded BTK and inhibited growth in multiple MCL cell lines.
  • Experimental analysis utilized a mouse model to evaluate the therapeutic potential of BTK-PROTAC C23.
  • Results suggest that overcoming BTK inhibitor resistance may become feasible, supporting further investigation into PROTAC applications.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc2chttps://doi.org/10.1182/blood-2025-7852
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.2025 · 1 citations
  2. 2Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?2025 · 6 citations
  3. 3Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders2025
  4. 4Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma2025
  5. 5Discovery of <b>TQ-3959</b> as a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell Malignancies2025 · 8 citations